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BACKGROUND: This multicentre randomised phase III trial was designed to determine whether adjuvant chemotherapy with
gemcitabine improves the outcomes of patients with resected pancreatic cancer.
METHODS: Eligibility criteria included macroscopically curative resection of invasive ductal carcinoma of the pancreas and no earlier
radiation or chemotherapy. Patients were randomly assigned at a 1:1 ratio to either the gemcitabine group or the surgery-only
group. Patients assigned to the gemcitabine group received gemcitabine at a dose of 1000mgm
 2 over 30min on days 1, 8 and 15,
every 4 weeks for 3 cycles.
RESULTS:Between April 2002 and March 2005, 119 patients were enrolled in this study. Among them, 118 were eligible and analysable
(58 in the gemcitabine group and 60 in the surgery-only group). Both groups were well balanced in terms of baseline characteristics.
Although heamatological toxicity was frequently observed in the gemcitabine group, most toxicities were transient, and grade 3 or 4
non-heamatological toxicity was rare. Patients in the gemcitabine group showed significantly longer disease-free survival (DFS) than
those in the surgery-only group (median DFS, 11.4versus 5.0 months; hazard ratio¼0.60 (95% confidence interval (CI): 0.40–0.89);
P¼0.01), although overall survival did not differ significantly between the gemcitabine and surgery-only groups (median overall
survival, 22.3 versus 18.4 months; hazard ratio¼0.77 (95% CI: 0.51–1.14); P¼0.19).
CONCLUSION: The current results suggest that adjuvant gemcitabine contributes to prolonged DFS in patients undergoing
macroscopically curative resection of pancreatic cancer.
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Pancreatic cancer remains to be one of the most challenging
malignancies to treat. Surgical resection offers the only opportu-
nity for cure. However, as no valid method for early detection of
this disease has been established, 80% or more of patients present
with unresectable disease at the time of diagnosis. Furthermore,
even when resection is performed, the recurrence rate is extremely
high, resulting in the 5-year survival rate of patients with resected
pancreatic cancer being no more than 20% (Evans et al, 1997).
As surgical resection alone has limitations, development of
non-surgical treatments, including adjuvant therapy, is needed to
improve the prognosis of patients with pancreatic cancer.
Several previous studies have suggested the efficacy of adjuvant
chemoradiotherapy and/or chemotherapy for the treatment
of resected pancreatic cancer (Kalser and Ellenberg, 1985;
Neoptolemos et al, 2004; Stocken et al, 2005; Hazard et al, 2007).
In the United States, adjuvant chemoradiation with fluorouracil
has become the standard of care after the Gastrointestinal Tumour
Study Group study showed a statistically significant improvement
in survival as compared with surgery-only (median overall
survival, 20 versus 11 months; 2-year survival rate, 42 versus
15%) (Kalser and Ellenberg, 1985). Recently, an evaluation of
Medicare patients derived from the SEER database showed a
survival advantage for patients who received adjuvant chemo-
radiotherapy as compared with patients who did not (3-year
survival rate, 45 versus 30%) (Hazard et al, 2007). On the other
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shand, no survival benefit of adjuvant chemoradiation was shown
by the European Study Group for Pancreatic Cancer (ESPAC)-1
trial, a large-scale phase III study conducted in Europe
(Neoptolemos et al, 2004). In the ESPAC-1, chemotherapy using
fluorouracil plus leucovorin, but not chemoradiation, showed
efficacy in the adjuvant setting: for patients who received
postoperative chemotherapy compared with those who did not,
the 2-year survival rates (40 versus 30%) and the 5-year survival
rates (21 versus 8%) were significantly greater. Therefore, although
the benefit of adjuvant therapy has become more apparent in
recent years, the optimal treatment modality remains controversial
(Ueno and Kosuge, 2008; Zuckerman and Ryan, 2008).
As for unresectable advanced pancreatic cancer, gemcitabine
has been widely employed, since Burris et al (1997) reported
results of a phase III study. The results of this study suggested that
patients receiving gemcitabine experienced improved survival as
compared with those receiving fluorouracil (median overall
survival, 5.65versus 4.42 months; P¼0.0025). The efficacy and
tolerability of gemcitabine for advanced pancreatic cancer have
been confirmed by several subsequent studies (Berlin et al, 2002;
Moore et al, 2003; Rocha Lima et al, 2004), and gemcitabine has
become the standard therapy for unresectable pancreatic cancer.
These facts led investigators to evaluate gemcitabine in the
adjuvant setting for patients with resected pancreatic cancer.
In 2005, a large phase III study, CONKO-001 (Charite ´
Onkologie), was presented at the American Society of Clinical
Oncology (ASCO) Annual Meeting by a German group (Oettle
et al, 2007). CONKO-001 compared a gemcitabine therapy group
with a surgery-only group after macroscopically curative resection
of pancreatic cancer. In CONKO-001, disease-free survival (DFS)
was significantly longer in the gemcitabine than in the observation
group (median DFS, 13.4 versus 6.9 months; Po0.001). However,
overall survival did not differ significantly between the gemcita-
bine and surgery-only groups, although the survival period tended
to be longer in the gemcitabine than in the observation group
(median, 22.1 versus 20.2 months; P¼0.06).
Coincidentally, at approximately the same time as the
CONKO-001, our multicentre randomised phase III trial, JSAP-02
(Japanese Study Group of Adjuvant Therapy for Pancreatic
Cancer), was being conducted to test whether the addition of
adjuvant gemcitabine to surgery would improve the outcomes of
patients with resected pancreatic cancer. The JSAP-02 study design
basically resembled that of CONKO-001, except for the planned
number of gemcitabine cycles: six cycles of gemcitabine were used
in CONKO-001 and three cycles in our study. To our knowledge,
this is the first randomised phase III trial of adjuvant gemcitabine
in an Asian population.
PATIENTS AND METHODS
Trial design
JSAP-02 was conducted at 10 centres in Japan. The trial was
supported by funding from the Health and Labour Sciences
Research Grant for Clinical Cancer Research from the Ministry of
Health, Labour and Welfare, Japan.
The primary end point was overall survival. Secondary end
points were DFS and gemcitabine safety. The ethics boards of all
institutions approved the protocol and all patients provided a
written, informed consent. The trial was conducted in accordance
with the World Medical Association Declaration of Helsinki and
Japanese Good Clinical Practice guidelines. The trial was
monitored for excessive toxicity by the Data Monitoring Commit-
tee, which functions independently of the JSAP. Data were
collected using the web-based clinical trial management system
at the data centre (EPS Co., Ltd., Osaka, Japan), and additional
changes were locked out of the database on 31 March 2009.
Patient eligibility
Patients who underwent macroscopically curative resection of
pancreatic cancer were enrolled in the study 3 to 10 weeks after
surgery. The other eligibility criteria were histologically proven
invasive ductal carcinoma of the pancreas; no history of earlier
chemotherapy or radiotherapy for pancreatic cancer except intra-
operative radiotherapy; age 20–74 years; Karnofsky performance
status of 50 or more; and adequate organ function (WBC count
X4000 and p12000mm
 3; neutrophil count X2000mm
 3;
platelet count X100000mm
 3; haemoglobin level X9.0g per
100ml; serum total bilirubin level p3.0mg per 100ml; serum
aspartate aminotransferase and serum alanine aminotransferase
level p5 times the upper limit of the normal range; and serum
creatinine level lesser than or equal to the upper limit of the normal
range). The exclusion criteria were pulmonary fibrosis or inter-
stitial pneumonia; clinically significant pleural effusions; presence
of distant metastasis (except distant lymph node metastasis
confirmed by resected specimen); other concomitant malignant
disease; active infection; history of serious complications related to
surgery; active gastrointestinal ulcers; history of myocardial
infarction within 3 months; severe mental disorder; pregnant or
lactating women; and other serious concomitant systemic disorders
incompatible with the trial in the investigator’s judgment.
Treatment plan
Patients were enrolled, within 10 weeks after surgery, through fax
by the staff at the data centre. Patients were randomly assigned at a
1:1 ratio to either the gemcitabine group or the surgery-only
group using the minimisation method stratified by resection status
(R0 versus R1), pathological stage (I–II versus III–IV) and
enrollment centre. Stage classification and the evaluation of
resected specimens were performed in accordance with the fifth
edition of the tumour–node–metastasis classification system of
the International Union Against Cancer. Patients assigned to the
gemcitabine group received gemcitabine at a dose of 1000mgm
 2
over 30min on days 1, 8 and 15 every 4 weeks. This 4-week cycle
was repeated for 3 cycles. If patients developed leukocyte counts of
o2000mm
 3 or 412000mm
 3, or platelet counts of
o75000mm
 3 during chemotherapy, gemcitabine administration
was stopped until recovery. When patients had grade 4 leukopenia
or neutropenia, febrile neutropenia or infection with grade 3
leukopenia or neutropenia, a platelet count of o25000mm
 3,o r
non-heamatological toxic effects of grade 3 or greater, a dose
reduction of gemcitabine from 1000mgm
 2 to 800mgm
 2 was
allowed. The surgery-only group received no anticancer treatment
after surgery, unless there was a confirmed relapse.
Assessments
Baseline assessments included medical history, physical examination,
vital signs, chest radiography, ECG, routine laboratory tests, and the
tumour markers CEA and CA19-9. Patients in the gemcitabine group
underwent laboratory tests and assessment of clinical symptoms every
week during the treatment period and every 3 months after completing
adjuvant chemotherapy. Patients in the surgery-only group underwent
similar examinations every 3 months. Adverse events were assessed
according to the Common Toxicity Criteria of the National Cancer
Institute (version 2.0). Patients in both groups underwent computed
tomography and/or ultrasonography at 3-month intervals after surgery,
unless there was a confirmed relapse. Tumour markers, CEA and
CA19-9, were also measured every 3 months until relapse.
Statistical analysis
A total of 116 patients were required to detect a hazard ratio of 0.55
with 80% power at a two-sided 0.05 significance level, which
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scorresponds to a 20% increase in the 2-year overall survival rate in
the surgery-only group versus the gemcitabine group (15 versus
35%, respectively).
All randomised and eligible patients were included in the intent-
to-treat (ITT) population for efficacy analyses. Efficacy analyses
were also performed in subpopulations stratified by resection
status (R0 versus R1) and pathological stage (I–II versus III–IV).
For safety analyses of gemcitabine, only patients who received
adjuvant gemcitabine were included. Overall survival was defined
as the period between randomisation and death. All deaths,
including those from other diseases, were considered to be events.
Disease-free survival was defined as the period between randomi-
sation and the occurrence of an event—relapse or death—
whichever came first. Data for patients who had not had an event
were censored, as of the date of the final observation. The Kaplan–
Meier method was used to estimate the overall survival or DFS and
the log-rank test was used for comparisons between the two
groups. The Wilcoxon test, Fisher’s exact test and the Mantel trend
test were used to compare differences among pretreatment
characteristics between the two groups. P-values of less than 0.05
were considered to indicate statistical significance. All statistical
analyses were performed using SAS version 9.1 statistical software
(SAS Institute Inc, Cary, NC, USA).
RESULTS
Characteristics of patients
Between April 2002 and March 2005, 119 patients in total were
enrolled at 10 centres. After randomisation, one patient in the
gemcitabine group was found to be ineligible because of a low
WBC count at baseline. Therefore, 118 eligible patients (58 in the
gemcitabine group and 60 in the surgery-only group) were
included in the ITT population for efficacy analyses (Figure 1).
No patients assigned to the surgery-only group received post-
operative anticancer treatment until a confirmed relapse. The two
groups were well balanced with regard to baseline characteristics
(Table 1). In total, 16% of the patients had a microscopically
positive margin (R1) and 69% had nodal metastases (N1). The
median follow-up period for surviving patients was 60.4 months
(range, 40.6–77.1 months) on the analysis cut-off date of 31 March
2009.
Treatment administration
Among the 58 patients in the gemcitabine group, one withdrew
from the study before treatment because of a postoperative
complication. Six patients (10%) discontinued treatment within 1
cycle, 7 (12%) after 2 cycles and 44 (76%) completed the scheduled
3 cycles of treatment. The reasons for withdrawal from treatment
included adverse events or complications (10 patients), the
detection of recurrent disease (2 patients) and patient preference
(2 patients). The dose of gemcitabine was decreased in one patient
because of neutropenia. The median number of cycles and the
median number of gemcitabine doses administered were 3 and 8,
respectively. The median dose intensity of gemcitabine was
667mgm
 2 per week, and the median relative dose intensity was
89%.
Safety
Of the 58 eligible patients assigned to the gemcitabine group,
adverse events were analysed in 57 patients who received at least
one dose of gemcitabine. Major grade 3 or 4 adverse events
observed during the treatment are listed in Table 2. Adjuvant
gemcitabine was generally well tolerated. Although high frequen-
cies of grade 3 or 4 leukopenia and neutropenia were experienced
(25 and 70%, respectively), most myelosuppression resolved
promptly without complications.
Three fatal events occurred during the study period: two in the
gemcitabine group and one in the surgery-only group. Of the two,
an association with gemcitabine could not be ruled out in one
patient who developed an abdominal abscess without neutropenia
after two treatment cycles and died from gastrointestinal bleed 183
days after the final gemcitabine administration.
DFS and overall survival
At the time of analysis, 44 patients in the gemcitabine group and
53 in the surgery-only group had recurrent disease. The common
sites of first recurrence were the liver, peritoneum and local
recurrence (Table 3). The recurrence pattern was similar in the
two groups. DFS was significantly longer in the gemcitabine
group than in the surgery-only group, with an estimated hazard
ratio of 0.60 (95% confidence interval (CI), 0.40–0.89; P¼0.01;
119 Patients randomised
59 Assigned to receive gemcitabine 60 Assigned to surgery-only
1 Excluded (ineligible)
58 Included in primary analysis
(intent-to-treat)
44 Completed 3 courses of treatment
1 Did not start treatment
13 Discontinued treatment
60 Included in primary analysis
(intent-to-treat)
57 Included in safety analysis
Figure 1 Flow chart of study subjects.
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sFigure 2). Median DFS was 11.4 months (95% CI, 8.0–14.5) in
the gemcitabine group versus 5.0 months (95% CI, 3.7–8.9) in
the surgery-only group. The estimated DFS rates at 6, 12 and 24
months were 70.7, 49.0 and 27.2% in the gemcitabine group, and
43.3, 26.7 and 16.7% in the surgery-only group, respectively.
Subgroup analyses showed that the beneficial effect of adjuvant
gemcitabine on DFS was evident for R0, N0 and stage I–II
patients (Table 4, Figure 3).
At the time of analysis, 98 patients (83%) had died (45 patients
in the gemcitabine group and 53 in the surgery-only group). The
causes of death in the gemcitabine group and surgery-only
groups were as follows: relapse (41 and 52 patients, respectively),
a d v e r s ee v e n t s( 2a n d1p a t i e n t s ,r e s p e c t i v e l y )a n du n k n o w n
causes (2 and 0 patients, respectively). Log-rank analysis
revealed no statistically significant difference in survival
estimates between the treatment groups (hazard ratio, 0.77
(95% CI, 0.51–1.14); P¼0.19; Figure 4). Median overall survival
was 22.3 months in the gemcitabine group (95% CI, 16.1–30.7)
versus 18.4 months in the surgery-only group (95% CI, 15.1–
25.3). The estimated overall survival rates at 6, 12, 18, 24 and 60
months were 94.8, 77.6, 58.6, 48.3 and 23.9% in the gemcitabine
group, and 85.0, 75.0, 53.3, 40.0 and 10.6% in the surgery-only
group, respectively. Subgroup analyses failed to show the
beneficial effect of adjuvant gemcitabine on overall survival,
although the survival period tended to be longer in the
gemcitabine than in the observation group for R0, N0 and stage
I–II patients (Table 4).
Table 1 Baseline characteristics
Gemcitabine
(n¼58)
Surgery-only
(n¼60) P-value
Characteristic No. % No. %
Age (years)
Median 65 64 0.62
Range 41–74 36–74
Sex
Women 18 31 26 43 0.19
Men 40 69 34 57
Days from surgery to randomisation (days)
Median 44 47 0.45
Range 22–71 22–70
Karnofsky performance status
Median 90 90 0.83
Range 70–100 70–100
Intra-operative radiotherapy
Yes 27 47 34 57 0.36
No 31 53 26 43
Primary site
Head 42 72 42 70 0.84
Body-tail 16 28 18 30
Maximal tumour size (cm)
Median 3.5 3.5 0.27
Range 1.0–10.0 1.2–7.0
Resection status
R0 47 81 52 87 0.46
R1 11 19 8 13
Primary tumour size
T1 6 10 6 10 0.90
T 2 12 46
T3 31 53 28 47
T4 20 35 22 37
Nodal status
N0 19 33 18 30 0.84
N1 39 67 42 70
Pathological stage
a
I 3 5 4 7 0.82
II 10 17 10 17
III 21 36 22 37
IV 24 41 24 40
Grading
1 18 31 16 27 0.80
23 3 5 7 3 6 6 0
35 9 4 7
Unknown 2 3 4 7
Histology
Adenocarcinoma 56 97 56 93 0.68
Other 2 3 4 7
CEA (ngml
 1)
Median 3.7 4.6 0.34
Range 0.9–252 0.5–74
CA19–9 (Uml
 1)
Median 33.2 37.5 0.40
Range 0–10435 0–46100
Abbreviations: CEA¼carcinoembryonic antigen; CA 19–9¼carbohydrate antigen
19–9.
aUICC fifth edition.
Table 2 Grade 3 and 4 adverse events in the gemcitabine group
(n¼57)
Gemcitabine
Grade 3
a Grade 4
a
Adverse event No. % No. %
Heamatological
Leukopenia 13 23 1 2
Neutropenia 32 56 8 14
Anaemia 2 4 0 0
Thrombocytopenia 1 2 0 0
Non-heamatological
Diarrhoea 1 2 0 0
Fever 1 2 0 0
Nausea 0 0 1 2
Anorexia 1 2 1 2
Fatigue 1 2 0 0
AST 3 5 0 0
ALT 4 7 0 0
Abscess 0 0 1 2
Abbreviations: ALT¼alanine aminotransferase; AST¼aspartate aminotransferase.
aNCI Common Toxicity Criteria, version 2.0.
Table 3 Patterns of initial recurrence
Gemcitabine Surgery-only
No. % No. %
Local 10 23 17 32
Liver 13 30 16 30
Peritoneum 8 18 7 13
Other 12 27 12 23
Unknown 1 2 1 2
Adjuvant gemcitabine for pancreatic cancer
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sDISCUSSION
We found that DFS in patients with resected pancreatic cancer was
significantly improved with three cycles of adjuvant gemcitabine as
compared with surgery-only, with an estimated hazard ratio of 0.60
(P¼0.01). However, a statistically significant improvement in overall
survival was not shown in this study, although median overall
survival, and 2-year and 5-year survival rates were favourable in the
gemcitabine group as compared with the surgery-only group. These
results were similar to those of the previously reported phase III trial
of adjuvant gemcitabine, CONKO-001 (Oettle et al, 2007).
CONKO-001 compared six cycles of gemcitabine with surgery-only
after macroscopically curative resection of pancreatic cancer. Table 5
shows a comparison of our study (JSAP-02) and CONKO-001. The
study design of JSAP-02 basically resembled that of CONKO-001
except for the planned sample size, number of gemcitabine cycles,
weeks from surgery to randomisation and eligibility criteria
determined by postoperative tumour markers. Baseline patient
characteristics, including resection status and nodal status, were
similar between the two studies. As for efficacies, although both
studies failed to show a statistically significant improvement in overall
survival, a significantly better DFS was shown with the adjuvant
gemcitabine. The data on DFS and overall survival reported in JSAP-
02 were comparable with those in CONKO-001.
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Time from randomization (months)
No. at risk
Gemcitabine
Surgery-only
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Surgery-only
Log-rank test  P = 0.01
HR = 0.60 (95% CI: 0.40–0.89)
08 4 72 60 48 36 24 12
2 6 11 13 15 27 58
1 3 7 9 10 16 60
Figure 2 Kaplan–Meier estimates of disease-free survival. Intent-to-treat
analysis.
Table 4 Disease-free and overall survivals in the total entire population and subgroups
Disease-free survival Overall survival
No. Median (months) Median (months)
GEM Surgery-only GEM Surgery-only HR (95% CI) P-value GEM Surgery-only HR (95% CI) P-value
All patients 58 60 11.4 5.0 0.60 (0.40–0.89) 0.01 22.3 18.4 0.77 (0.51–1.14) 0.19
R0 47 52 11.4 5.1 0.58 (0.37–0.91) 0.02 26.8 19.1 0.70 (0.45–1.09) 0.11
R1 11 8 9.5 3.4 0.39 (0.15–1.06) 0.05 18.3 17.6 1.05 (0.41–2.72) 0.92
N0 19 18 — 9.0 0.38 (0.16–0.86) 0.02 32.0 28.4 0.63 (0.29–1.37) 0.24
N1 39 42 8.6 4.5 0.73 (0.46–1.16) 0.19 17.1 17.3 0.84 (0.53–1.34) 0.84
Stage I–II 13 14 — 10.0 0.27 (0.08–0.85) 0.02 67.8 — 0.42 (0.15–1.22) 0.10
Stage III–IV 45 46 8.9 4.6 0.68 (0.44–1.05) 0.08 18.3 16.3 0.82 (0.53–1.26) 0.36
Abbreviations: CI¼confidence interval; GEM¼gemcitabine; HR¼hazard ratio.
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Figure 3 Kaplan–Meier estimates of disease-free survival in patients with R0 or R1 resection. Intent-to-treat analysis.
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sThe CONKO-001 data were re-analysed in March 2008, and
presented at the ASCO Annual Meeting of that year as the final
results (Neuhaus et al, 2008). Although the improvement in overall
survival did not reach statistical significance (P¼0.06) in the
previous report (Oettle et al, 2007), the new CONKO-001 report
showed a significant difference in overall survival between the
gemcitabine and surgery-only groups after long-term observation
(median overall survival, 22.3 months versus 20.2 months; 5-year
survival rate, 21.0% versus 9.0%; P¼0.005). In contrast to these
final results of CONKO-001, our study, though the data were
analysed after an adequate observation period, failed to show a
survival benefit of adjuvant gemcitabine. As the JSAP-02 survival
curve itself resembled that of CONKO-001, the main reason for this
discrepancy may be the underpowered nature of our study. The
planned sample size for the JSAP-02, which was less than one-third
that of CONKO-001, might have been too small to detect a
significant difference in overall survival. Other factors that differed
between the two studies, including race, number of gemcitabine
cycles and patient selection based on postoperative tumour
markers, may also have influenced the outcome of our study.
Further study is needed to clarify the impacts of these factors on
adjuvant gemcitabine. Although intra-operative radiotherapy was
allowed only in our study and 52% of patients actually received this
treatment, its influence may be very small because a recent phase
III trial failed to show any benefits of intra-operative radiotherapy
in patients with resected pancreatic cancer (Kinoshita et al, 2009).
Adjuvant gemcitabine was well tolerated in our study. A total of
44 patients (76%) completed the three scheduled treatment cycles,
and the median relative dose intensity of gemcitabine was as good
as 89%. Although 70% of patients experienced grade 3 or 4
neutropenia during adjuvant gemcitabine therapy, most of these
toxicities were transient, and serious adverse events were rare. The
frequencies of grade 3 or 4 neutropenia induced by gemcitabine
monotherapy are reportedly 20–30% (Aapro et al, 1998). The
reasons for marked heamatological toxicities occurring in our
study are unclear, although surgical stress might have exacerbated
myelosuppression. Onoue et al (2004) reported that administering
gemcitabine to patients after surgical resection resulted in more
severe leukopenia, as compared with patients not undergoing
resection (grade 3 or 4 leukopenia, 57 versus 25%; P¼0.048).
Although our study, similar to CONKO-001, showed the safety of
adjuvant gemcitabine, cautious selection of patients and careful
observation of treatment will be necessary when giving this agent
to patients with resected pancreatic cancer.
Other than gemcitabine, fluorouracil-based chemotherapy is
now considered to be an option for adjuvant therapy for resected
pancreatic cancer based on the results of ESPAC-1. The ESPAC-1
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Figure 4 Kaplan–Meier estimates of overall survival. Intent-to-treat
analysis.
Table 5 Comparison between the current Japanese study and CONKO-001
Current study (JSAP-02) CONKO-001
a
Gemcitabine Surgery-only Gemcitabine Surgery-only
Study design
Planned sample size 116 368
Planned number of gemcitabine cycles 3 — 6 —
Planned weeks from surgery to randomisation p10 p6
Selection based on postoperative tumour markers No requirement p2.5 times the upper
limit of normal
Baseline patient characteristics
No. of patients 58 60 179 175
Median age (years) 65 64 62 61
Sex: men 69% 57% 59% 56%
Median Karnofsky PS 90 90 80 80
Resection status: R0 81% 87% 81% 85%
Nodal status: N0 33% 30% 29% 27%
Median days from surgery to randomisation 44 47 22 24
Results
Median DFS (months) 11.4 5.0 13.4 6.9
1-year DFS rate 49% 27% 58% 31%
2-year DFS rate 27% 17% 31% 15%
P-value 0.01 o0.01
Median OS (months) 22.3 18.4 22.1 20.2
1-year OS rate 78% 75% 73% 73%
2-year OS rate 48% 40% 48% 42%
5-year OS rate 24% 11% 23% 12%
P-value 0.19 0.06
Abbreviations: DRF¼disease-free survival; OS¼overall survival; PS¼performance status.
aPreviously reported in Oettle et al (2007).
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leucovorin in 289 patients with resected pancreatic cancer
(Neoptolemos et al, 2004). The ESPAC group also performed a
pooled analysis using data from 458 patients who were enrolled in
ESPAC-1, ESPAC-1 plus or early ESPAC-3(v1) (Neoptolemos et al,
2009a). The overall survival was superior in patients randomised to
fluorouracil plus leucovorin, as compared with those randomised
to observation (pooled hazard ratio, 0.70; P¼0.003, median overall
survival, 23.2 versus 16.8 months), indicating the validity of using
fluorouracil plus leucovorin as adjuvant therapy.
With regard to the comparison between gemcitabine and
fluorouracil-based chemotherapy in the adjuvant setting, two large
phase III trials, RTOG 97-04 and ESPAC-3(v2), were recently
reported (Regine et al, 2008; Neoptolemos et al, 2009b). RTOG 97-
04 examined whether survival could be extended by substituting
gemcitabine for fluorouracil before and after fluorouracil-based
radiation. When the data from the entire population were
analysed, no significant difference in the survival period was
noted between the fluorouracil and gemcitabine groups, but the
gemcitabine group had better outcomes when the analysis was
confined to patients with pancreatic head cancer (median overall
survival, 20.5 versus 16.9 months, P¼0.033). ESPAC-3(v2) was
designed to compare fluorouracil plus leucovorin and gemcitabine
in patients with resected pancreatic cancer. In total, 1088 patients
were randomised in ESPAC-3(v2), and Neoptolemos et al reported
no significant difference in survival between adjuvant fluorouracil
plus leucovorin and adjuvant gemcitabine at the 2009 ASCO
Annual Meeting (hazard ratio, 0.94; P¼0.39, median overall
survival 23.0 versus 23.6 months). Although no significant
difference in survival was shown, gemcitabine may be suitable
for clinical use as adjuvant therapy because the rate of serious
adverse events in patients treated with gemcitabine was signifi-
cantly lower than that in patients treated with fluorouracil plus
leucovorin (7.5 versus 14%, Po0.001).
In recent years, new approaches, including novel cytotoxic or
molecular-targeting agents, have been actively applied in the
adjuvant setting for pancreatic cancer. In Japan, S-1, an oral
fluoropyrimidine derivative, has attracted the attention of
investigators on the basis the promising results of clinical trials
for advanced pancreatic cancer (Ueno et al, 2007; Okusaka et al,
2008). We are now conducting a phase I/II trial of gemcitabine plus
S-1 for resected pancreatic cancer (JSAP-03 trial). As well as
developing new effective treatments, individualised approaches
based on individual differences in drug metabolism are also
important in selecting patients who are more likely to benefit from
adjuvant gemcitabine. Several recent studies have suggested that
tumour-specific expression of human equilibrative nucleoside
transporter 1 may be a promising predictive biomarker of outcome
in pancreatic cancer patients receiving gemcitabine chemotherapy
(Spratlin et al, 2004; Giovannetti et al, 2006; Farrell et al, 2009;
Mare ´chal et al, 2009). Further investigation of and progress in
these new strategies are expected in the future.
In conclusion, adjuvant chemotherapy with gemcitabine sig-
nificantly improved DFS, as compared with surgery-only
in patients with resected pancreatic cancer. Our study supports
the conclusions of the CONKO-001 as well as the validity of
using gemcitabine as adjuvant therapy for resected pancreatic
cancer.
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